BIRC5 and gastric cancer: Compared to normal controls, the overexpression of Survivin was associated with worse outcome in gastric cancer among 11 studies (863 patients and 839 controls; OR  = 83.622, 95% CI  = 46.476–150.455, P<0.001) (Table 3).